MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio

MeMed has also developed the MeMed COVID-19 Severity™ test for predicting severe outcomes in COVID-19 patients, which has been cleared for use in Europe. Eran Eden, MeMed’s co-founder and CEO, said: “This new investment will enable MeMed to expand operations with a focus on the U.S.

https://memes.com/

Memed Raises $93M To Accelerate Commercialization Of Its Host Immune-Response Product Portfolio

Description

Company Information

Funding Insights

Memed Raises $93M To Accelerate Commercialization Of Its Host Immune-Response Product Portfolio

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information